Empowering Communities Through Digital Health: The Techquity by FAITH! Digital Health Advocate Training
Transforming Lives with Digital Health Advocacy The Mayo Clinic’s FAITH! [...]
Amgen Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
MariTide Demonstrated up to ~20% Average Weight Loss at 52 [...]
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
– Attruby is the first and only approved product with a [...]
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Acoramidis demonstrated the earliest known time to separation in cardiovascular [...]